Deciphering the Pivotal Role of Nanoformulations of Vinca Alkaloids in Cancer: Preclinical, Clinical, and Patent Status
Letters in Applied NanoBioScience · 30.06.2026 · 15 (2)
DOI: 10.33263/lianbs152.071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Applied NanoBioScience, online erschienen am 30.06.2026. Verfasst von Sukhbir Singh und 4 weiteren Autor:innen. Die Arbeit nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is the leading cause of disease-related mortality worldwide, characterized by the uncontrolled and rapid proliferation of abnormal cells. Vinca alkaloids (VAs) exert their anticancer effects by forming a tubulin-alkaloid complex by binding to microtubules. Vinblastine and vincristine are recognized as natural chemicals, whereas vindesine and vinorelbine are semi-synthetic derivatives. VAs have restricted therapeutic applicability due to several factors, including their poor bioavailability, extensive first-pass metabolism in the liver, significant side effects, and the development of multidrug resistance. Nanotechnology is a promising field that uses nanoparticles to diagnose diseases and develop drug-delivery systems to prevent and manage life-threatening conditions such as cancer. Nanoformulations of VAs, such as magnetic nanoparticles, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, liposomes, niosomes, polymeric micelles, and inorganic nanoparticles, have been investigated for potential applications in cancer therapy. These studies have shown enhanced pharmacokinetics, targeted delivery to tumor cells, greater penetration, and improved chemotherapy outcomes. For example, the MTT assay revealed that TPGS emulsified vinorelbine solid lipid nanoparticles were 39.5-fold more effective compared to plain vinorelbine. This review encompasses preclinical and clinical investigations of nanoformulations of VAs in cancer therapies. Liposomal vincristine, used both as monotherapy and in combination, has demonstrated anticancer activity in refractory cancers, non-Hodgkin lymphoma, acute lymphoblastic leukemia, retinoblastoma, and malignant melanoma, according to clinical research. Apart from this, this review also analyses published patents pertaining to the anticancer properties of VAs nanoformulations.
Zitieren
APA
Singh, S., Samantha, Sharma, N., Gupta, S., & Kumar, P. (2026). Deciphering the Pivotal Role of Nanoformulations of Vinca Alkaloids in Cancer: Preclinical, Clinical, and Patent Status. Letters in Applied NanoBioScience, 15(2). https://doi.org/10.33263/lianbs152.071
Vancouver
Singh S, Samantha, Sharma N, Gupta S, Kumar P. Deciphering the Pivotal Role of Nanoformulations of Vinca Alkaloids in Cancer: Preclinical, Clinical, and Patent Status. Letters in Applied NanoBioScience. 2026;15(2). doi:10.33263/lianbs152.071
BibTeX
@article{Singh2026,
author = {Singh, Sukhbir and Samantha and Sharma, Neelam and Gupta, Sumeet and Kumar, Philips},
title = {Deciphering the Pivotal Role of Nanoformulations of Vinca Alkaloids in Cancer: Preclinical, Clinical, and Patent Status},
journal = {Letters in Applied NanoBioScience},
year = {2026},
volume = {15},
number = {2},
doi = {10.33263/lianbs152.071}
}
EUVIMED